Skinvisible (SKVI) Common Equity (2010 - 2026)

Skinvisible has disclosed Common Equity across 17 years of filings, most recently posting -$10.8 million for Q2 2026.

• In Q2 2026, Common Equity fell 10.57% year-over-year to -$10.8 million; the TTM figure through Jun 2026 stood at -$10.8 million (down 10.57% YoY), while the FY2025 annual figure was -$10.3 million, down 11.27% from the prior year.
• Common Equity came in at -$10.8 million for Q2 2026 at Skinvisible, down from -$10.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$5.6 million in Q1 2022 to a low of -$10.8 million in Q2 2026.
• Average Common Equity over 5 years is -$8.7 million, with a median of -$9.3 million recorded in 2024.
• Year-over-year, Common Equity slumped 44.85% in 2023 and decreased 1.39% in 2025.
• Over 5 years, Common Equity stood at -$6.6 million in 2022, then plunged by 35.88% to -$9.0 million in 2023, then decreased by 2.22% to -$9.2 million in 2024, then declined by 11.27% to -$10.3 million in 2025, then retreated by 5.09% to -$10.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$10.8 million in Q2 2026, -$10.5 million in Q1 2026, and -$10.3 million in Q4 2025.